Literature DB >> 9884334

Targeting of functional antibody-CD59 fusion proteins to a cell surface.

H F Zhang1, J Yu, E Bajwa, S L Morrison, S Tomlinson.   

Abstract

Complement is involved in the pathogenesis of many diseases, and there is great interest in developing inhibitors of complement for therapeutic application. CD59 is a natural membrane-bound inhibitor of the cytolytic complement membrane attack complex (MAC). In this study, the preparation and characterization of antibody-CD59 (IgG-CD59) chimeric fusion proteins are described. Constructs were composed of soluble CD59 fused to an antibody-combining site at the end of CH1, after the hinge (H), and after CH3 Ig regions. The antigen specificity of each construct was for the hapten 5-dimethylamino-naphthalene-1-sulfonyl (dansyl). Correct folding of each IgG-CD59 fusion partner was indicated by recognition with anti-CD59 antibodies specific for conformational determinants and by IgG-CD59 binding to dansyl. The IgG-CD59 fusion proteins all bound specifically to dansyl-labeled Chinese hamster ovary cells and provided targeted cells, but not untargeted cells, with effective protection from complement-mediated lysis. Data indicate that CD59 must be positioned in close proximity to the site of MAC formation for effective function, and that modes of membrane attachment other than glycophosphatidylinositol linkage can affect CD59 functional activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9884334      PMCID: PMC407863          DOI: 10.1172/JCI4607

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Membrane defenses against attack by complement and perforins.

Authors: 
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation.

Authors:  R H Daniels; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Immunopathology of hyperacute xenograft rejection in a swine-to-primate model.

Authors:  J L Platt; R J Fischel; A J Matas; S A Reif; R M Bolman; F H Bach
Journal:  Transplantation       Date:  1991-08       Impact factor: 4.939

4.  Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.

Authors:  L K Tan; R J Shopes; V T Oi; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 5.  Membrane signaling by complement C5b-9, the membrane attack complex.

Authors:  A Nicholson-Weller; J A Halperin
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

6.  Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.

Authors:  S A Rollins; J Zhao; H Ninomiya; P J Sims
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

7.  Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.

Authors:  P Moran; H Beasley; A Gorrell; E Martin; P Gribling; H Fuchs; N Gillett; L E Burton; I W Caras
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

8.  Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.

Authors:  J Hill; T F Lindsay; F Ortiz; C G Yeh; H B Hechtman; F D Moore
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

9.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

Authors:  H F Weisman; T Bartow; M K Leppo; H C Marsh; G R Carson; M F Concino; M P Boyle; K H Roux; M L Weisfeldt; D T Fearon
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

10.  Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.

Authors:  K R Kalli; P H Hsu; T J Bartow; J M Ahearn; A K Matsumoto; L B Klickstein; D T Fearon
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  14 in total

1.  Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

Authors:  R J Quigg; C He; B K Hack; J J Alexander; B P Morgan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Expression of complement regulating factors in gastric cancer cells.

Authors:  T Inoue; M Yamakawa; T Takahashi
Journal:  Mol Pathol       Date:  2002-06

3.  Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.

Authors:  Chen Song; Zhikai Xu; Jianting Miao; Jiang Xu; Xingan Wu; Fanglin Zhang; Hong Lin; Zhuyi Li; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

4.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

5.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

6.  An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice.

Authors:  Marieta M Ruseva; Valeria Ramaglia; B Paul Morgan; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

7.  Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.

Authors:  Hongbin Song; Chun He; Christian Knaak; Joel M Guthridge; V Michael Holers; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 8.  New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.

Authors:  V Michael Holers; Stephen Tomlinson; Liudmila Kulik; Carl Atkinson; Bärbel Rohrer; Nirmal Banda; Joshua M Thurman
Journal:  Semin Immunol       Date:  2016-06-06       Impact factor: 11.130

9.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.